On November 3, President Shavkat Mirziyoyev reviewed a presentation on improving medical care for children with orphan diseases, the implementation of reforms in the pharmaceutical sector, and new projects.
In our country, a system of medical and social assistance has been established aimed at preventing the birth of children with hereditary and congenital diseases, timely diagnosis and treatment of children with rare (orphan) diseases.
Today, a total of 2,174 children with 5 types of orphan and hereditary-genetic diseases are provided with free diagnostics, medicines, and special therapeutic food at the expense of the state budget.
At the same time, as a result of the improvement in the quality of diagnostics of these types of diseases, new types of orphan diseases are being identified, and the number of children in need of treatment is increasing.
The presentation provided information on the Program of Measures for the Organization of Medical and Social Assistance to Children with Rare (Orphan) and Other Hereditary-Genetic Diseases for 2026-2030.
According to it, from now on, the number of diseases covered by state treatment will be increased from 5 to 10, the age limit is extended from 18 to 21.
A total of 961 billion soums is planned to be allocated for the implementation of the program in 2026-2030.
The Head of State signed a corresponding resolution and approved the program.
The President was also presented with projects for the production of pharmaceutical products, attracting investments to the industry, implementing projects in the industrial zone of the "Tashkent Pharma Park" pharmaceutical cluster, and the work being carried out to ensure quality and safety.
Industry enterprises produced products worth 5 trillion soums, exported products worth 172 million dollars, and invested 286 million dollars, of which 257 million dollars were foreign investments.
Production of 205 types of medicines has been established by 35 domestic enterprises, and the number of countries exporting them has reached 55. This year alone, 16 projects worth 29 million dollars were launched, and 830 new jobs were created.
To ensure quality and safety, the GMP standard has been implemented in 61 drug manufacturers, the GDP standard in 486 distributor warehouses, and the GPP standard in 9,450 pharmacies.
Does not exist in the price registry of reference countries.
According to the proposed measures, from January 1, 2026, the cost of 2.6 thousand types of prescription drugs is expected to decrease by an average of 40-50 percent.
During the presentation, information was also presented on measures to further improve the mechanisms of state procurement of pharmaceutical products.
In order to eliminate the procurement of low-quality products and corruption in hospitals, all state procurements will now be carried out through the special electronic system "farma.xarid.uz."
After the launch of this electronic system, only participants with all necessary certificates for production, delivery, and product safety (GMP, ISO:13485 GDP) will be able to participate in public procurement.
In the process of public procurement, the system automatically checks that the price of products does not exceed the established reference prices.
The Head of State instructed to develop, by January 1, 2026, within the framework of this system, a special platform for the formation of the need for medicines and medical equipment in state medical institutions and the effective management of waste.
The President was also presented with a new procedure for state registration of medicines and medical devices in order to provide the population with high-quality, safe, and effective medicines.
According to it, the production of medicines will be established through technology transfer. The possibility of production by foreign pharmaceutical companies using the capacities of domestic manufacturers and state registration in an expedited manner will be created.
The possibility of introducing into medical practice drugs of a new type, belonging to the category of biomedical cell products, used to treat damaged tissues, grow parts of organs, and restore the functional capabilities of the body, will be created.
Clinical trials and evaluation of the results of "Generic" drugs will be carried out in accordance with international standards, and the registration periods for them will be reduced.
From now on, medical equipment belonging to the 1st class according to the safety classification will not undergo laboratory tests (except for sterile, measuring and invasive medical equipment) and clinical trials.
The President approved the proposals and, by the end of 2025, plans to fully launch 32 investment projects worth 166 million dollars, create 1,500 new jobs, further increase the volume of production and exports, and develop a pharmaceutical complex.
Read “Zamin” on Telegram!
Users of Меҳмон are not allowed to comment this publication.
